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Abstract
The receptor for glycation end products (RAGE) has been previously implicated in shaping the adaptive immune response.
RAGE is expressed in T cells after activation and constitutively in T cells from patients with diabetes. The effects of RAGE on
adaptive immune responses are not clear: Previous reports show that RAGE blockade affects Th1 responses. To clarify the
role of RAGE in adaptive immune responses and the mechanisms of its effects, we examined whether RAGE plays a role in T
cell activation in a Th2 response involving ovalbumin (OVA)-induced asthma in mice. WT and RAGE deficient wild-type and
OT-II mice, expressing a T cell receptor specific for OVA, were immunized intranasally with OVA. Lung cellular infiltration and
T cell responses were analyzed by immunostaining, FACS, and multiplex bead analyses for cytokines. RAGE deficient mice
showed reduced cellular infiltration in the bronchial alveolar lavage fluid and impaired T cell activation in the mediastinal
lymph nodes when compared with WT mice. In addition, RAGE deficiency resulted in reduced OT-II T cell infiltration of the
lung and impaired IFNc and IL-5 production when compared with WT mice and reduced infiltration when transferred into
WT hosts. When cultured under conditions favoring the differentiation of T cells subsets, RAGE deficient T cells showed
reduced production of IFNc but increased production of IL-17. Our data show a stimulatory role for RAGE in T activation in
OVA-induced asthma. This role is largely mediated by the effects of RAGE on T cell proliferation and differentiation. These
findings suggest that RAGE may play a regulatory role in T cell responses following immune activation.
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Introduction
T cell activation is determined by intrinsic cellular factors
consisting of T cell receptor signaling (signal 1) and costimulatory
signals (signal 2). However, other extrinsic factors such as cytokines
and products of cell death also affect T cell activation,
differentiation, and survival by modulating cell intrinsic signals.
T cell differentiation may be affected by activating pathways
involving recruitment of lck and other signaling molecules. In
addition, activation of innate immune receptors and signaling
pathways can also modulate T cell differentiation.
Previous studies showed that the receptor for glycation end
products (RAGE) plays a role in activation and differentiation of T
cells[1,2,3,4]. Blockade of RAGE activation with soluble RAGE
attenuated the adoptive transfer of diabetes in NOD mice and also
reduced recurrent diabetes in syngeneic islet grafts and islet
allograft rejection [1]. This reduction in diabetes was correlated
with reduced cellular infiltration of the islet and increased
expression of anti-inflammatory cytokines such as IL-10 and
TGF-b [1]. Similarly, RAGE blockade results in reduced T cell
infiltration of the central nervous system in the experimental
autoimmune encephalomyelitis (EAE) model of multiple sclerosis
[5]. In transgenic mice expressing a T cell receptor specific for
ovalbumin (OVA) (OT-II), the transfer of RAGE-deficient OT-II
T cells into RAGE-sufficient hosts resulted in reduced proliferative
responses following OVA immunization. This effect was attribut-
able to the expression of RAGE on the OT-II T cells [2].
RAGE also appears to be involved in human immune
responses. Patients with chronic obstructive pulmonary disease
show increased RAGE expression in the lung and elevated soluble
RAGE levels in the bronchial alveolar fluid [5,6]. Similarly, a
recent report demonstrated increased RAGE receptor and ligand
levels in asthmatic patients [7], indicating an active role for RAGE
in lung inflammation. We reported constitutive expression of
RAGE in T cells isolated from diabetic patients but not healthy
donors [4].
These previous studies suggest that RAGE can modulate T cell
differentiation. Supernatants from cultures with anti-CD3 and
anti-CD28 mAbs showed higher levels of IL-10, IL-5, and TNF-
alpha secreted from activated RAGE2/2 compared with
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RAGE+/+ T cells, while RAGE inhibition in RAGE+/+ T cells
resulted in reduced production of IFN-c, suggesting that RAGE
may be important in the differentiation of Th1 cell subsets [2,3].
Furthermore, there was increased expression of RAGE mRNA in
clonal T cells activated under Th1differentiating conditions.
RAGE2/2 T cells showed increased production of Th2 type
cytokines including IL5 and IL10 in MLR responses, while RAGE
blockade resulted in decreased IFN-gamma production [3]. In
vivo stimulation of RAGE deficient OT-II OVA-specific T cells
with OVA showed decreased T cell activation and reduced
Th1cytokines. This effect was unique to T cells and was
independent of RAGE expression on DCs [2].
The reduced Th1 response and increased Th2 response in
RAGE deficient mice indicate that RAGE can control T helper
differentiation. To further evaluate the effect of RAGE on immune
mediated disease, we examined RAGE deficient mice for their
ability to respond to a Th2 like response induced with intranasal
OVA immunization model of asthma [8]. Our data show
reduction in T cell activation and infiltration of the lungs in




Homozygous RAGE-null mice[9] were backcrossed .10
generations into C57BL/6 and were mated with TCR-transgenic
mice expressing a TCR that recognizes OVA residues 323–339 in
the context of I-Ab C57BL/6-Tg(TcraTcrb)425Cbn (OT-II;
originally provided by Alan Frey, New York University School
of Medicine, New York, NY) [2]. C57BL/6 (termed B6.H2b) mice
were purchased from The Jackson Laboratory. All animals were
maintained in a temperature-controlled room with alternating 12-
h light/dark cycles. All experiments were approved by the
Institutional Animal Care and Use Committee of Yale University.
These studies conform to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health
(Bethesda, MD).
Intranasal immunization protocol
WT or RAGE2/2 mice were immunized with 100 mg of OVA
(Sigma Aldrich) on day 1,2, and 3. Animals received an additional
boost of 50 mg OVA intranasally on days 14 and 15 and on days
19 and 20. Mice were sacrificed on day 21 and their tissues were
collected for additional analysis. Intranasal immunization of OT-II
and OT-II/RAGE2/2 was done using 50 mg of OVA on day
1,2, and 3 followed by intranasal boost of 25 mg OVA on days 7, 8,
and 9. Mice were sacrificed on day 10 and their tissues were
collected for additional studies.
In some experiments, WT or RAGE2/2 OT-II cells (107)
were transferred into non-transgenic WT C57BL/6 recipients.
The mice were then immunized with intranasal OVA as described
above and the mediastinal LNs and lungs were isolated as
described below. Cell counts were performed and the cells were
analyzed for expression of Vb5.1/5.2 by flow cytometry as
described below.
Bronchial alveolar and lung collection
Bronchoalveolar lavage (BAL) was performed by cannulation of
the trachea and lavage with 1 ml of PBS. Total cell counts were
performed, and cells isolated for further analysis. Lungs were
collected and were process for either histology or FACS analysis as
described below.
T cell cultures
To assess the effects of RAGE on skewing of T cells, we
stimulated purified Tcells from WT or RAGE2/2 B6 mice with
plate bound anti-CD3 antibody (10 ug/ml) plus soluble anti-CD28
antibody (1 ug/ml) for four days under the following skewing
conditions: for Th1 anti-IL4 antibody (5 ug/ml), IL12 (3.5 ng/ml)
and IL2 (20 U/ml), for Th2 anti IFNc antibody (5 ug/ml), IL2
(20 U/ml), IL4 (10 ng/ml) and for Th17 both anti IL4 and anti
IFNc antibodies plus IL23 (20 ng/ml), IL6 (20 ng/ml), and TGF
beta (0.5 ng/ml). After four days of stimulation, the cells were
harvested from the wells, washed and replated in uncoated wells
for an overnight rest. The following day the resting cells were
harvested, run through a ficoll separation before counting and
replating in wells coated with anti-CD3. The cells were re-
stimulated for 24 hr and the supernatants were collected and
frozen at 280 until analysis by Luminex assay or by Elisa. For
these assays, antibodies and cytokines were obtained from Dr.
Richard Flavell’s laboratory.
Immunofluorescence staining
Lungs from OVA immunized mice were perfused using PBS,
mounted in OCT compound (Tissue-Tek) and snap frozen in
liquid nitrogen. Frozen tissues were sectioned at 7 mm thickness
and fixed using acetone. Hematoxylin staining was done to
evaluate lung infiltrating mononuclear cells. PE-conjugated rat
anti-mouse CD4 antibody (BD Pharmingen) was used to detect T
cell infiltration in OT-II transgenic mice.
FACS analysis
BAL fluid, lungs, and mediastinal LNs were analyzed by FACS
(FACSCalibur BD Biosciences). The following mAbs were used for
T cell analysis: rat anti-mouse CD4, rat anti-mouse CD8a, anti-
CD3e, allophycocyanin-conjugated rat anti-mouse CD25, anti-
CD62L, and anti-TCR Vb5.1/5.2 (all from BD Pharmingen).
Granulocytes in the BAL were detected using rat anti-mouse GR-1
(BD Pharmingen).
Cytokine measurement
Supernatants were removed from in vitro cultures of lymph
node cells harvested from primed mice and frozen until analyzed.
The cells were stimulated with or without OVA peptide and
Luminex assays were performed on the supernatants using the
Th1/Th2 cytokine 6plex panel (Invitrogen) or a murine 8plex kit
from Millipore. Supernatants were analyzed for the following
analytes: IL2, IL4, IL5, IL10, IL12, IL13, IL17, and IFNc,
following the kit protocols and assays were read on a Biorad
Bioplex analyzer (Biorad). In studies of T cell skewing, IFNc was
analyzed by ELISA.
Statistical Analyses
Unless otherwise indicated mean6SEM are shown. All
comparisons between WT and RAGE2/2 cells were done with
Student’s t-test using GraphPad Prism 5.
Results
Intranasal OVA treated RAGE deficient mice show
reduced cellular infiltration in the lung
Previous reports in both human and mouse show an increase in
RAGE expression during acute lung injury and a stimulatory role
for RAGE in murine T cell activation[10]. We therefore examined
whether RAGE deficiency affects overall immune activation and
cellular infiltration in mice immunized with intranasal-OVA.
RAGE in OVA-Induced Asthma
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Hematoxylin and eosin staining of lung sections from WT or
RAGE2/2 revealed an accumulation of mononuclear cell in the
lungs and airways of WT mice that was reduced in the lungs of
RAGE2/2 mice (Figure 1A). FACS analysis of the cellular
infiltrates from WT and RAGE2/2 mice showed a significant
reduction in the numbers of GR-1+ cells (Figure 1B, p,0.003),
and CD4+ T cells (Figure 1C, p,0.045) in the BAL fluid and lungs
of RAGE2/2 mice, respectively. In the mediastinal lymph nodes,
there were increased CD62L expressing CD4+ cells in
RAGE2/2 mice when compared with WT controls (Figure 1D,
p,0.035). These data suggest that RAGE expression is required
for normal immune activation and cellular infiltration in the lungs
of OVA treated mice.
OVA specific RAGE2/2 OT-II cells show reduced IFNc
and IL-5 production following OVA challenge
To more specifically examine the role of RAGE in mediating T
cell activation, we tested the effects of RAGE deficiency on lung
infiltrates of OVA-specific OT-II TCR transgenic T cells, and
their responses to OVA in vitro following OVA stimulation and
priming in vivo. RAGE deficient or sufficient OT-II mice were
immunized intranasally with OVA. Following activation, medias-
tinal LNs were collected and cells were tested in a recall response
assay. Luminex analysis of supernatant of OVA stimulated
RAGE2/2 OT-II cells showed reduced production of IL-5,
and IFNc (Figure 2A) and IL-10 (not shown). Immunofluorescence
staining of the lungs showed an accumulation of CD4+ cells in the
airways of both OT-II and RAGE2/2OT-II mice (Figure 2B).
There was a significant reduction in the percentage of CD4+Vb5+
OT-II cells in the lungs of RAGE2/2 mice when compared with
control mice (Figure 2C, p,0.042). Overall these data demon-
strate that RAGE deficient OVA specific CD4 T cells show
reduced cytokine production by cells from draining lymph nodes
and reduced cellular accumulation in the lung.
RAGE is highly expressed on pulmonary tissue [11]. In order to
determine whether the behavior of the RAGE2/2 T cells was
due to effects on T cells or were the result of RAGE deficiency on
the pulmonary tissue, we transferred WT or RAGE2/2 OT-II
transgenic T cells into WT non-transgenic hosts and challenged
the mice with intranasal OVA. There was a 43% reduction of the
OT-II cells in the draining lymph nodes and a reduced numbers of
OT-II T cells in the BAL fluid of the mice that had received
RAGE2/2 T cells (Figure 3, p = 0.08).
Figure 1. Cellular infiltration of the lung is reduced in OVA immunized RAGE2/2 mice. WT or RAGE2/2 mice were challenged with
intranasal OVA as described in Materials and Methods. (A) H&E staining of lungs of WT and RAGE2/2 mice. (B) Percent of Gr-1+ cells in the bronchial
alveolar lavage fluid of OVA immunized mice (n = 5 per group, ***p,0.003). (C) Absolute numbers of CD4+ in the lungs of OVA immunized mice (WT:
n = 15; RAGE2/2: n = 14; *p,0.045). (D) Percent of CD4+CD62L+ cells in the mediastinal LNs of OVA immunized mice (WT: n = 4, RAGE2/2: n = 5; *p,
0.035).
doi:10.1371/journal.pone.0095678.g001
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RAGE affects activation and differentiation of T cells
Our studies of OT-II cells showed reduced cytokine production,
Therefore, we sought to examine whether RAGE expression could
alter the differentiation into T cells into different phenotypes. To
address this, we cultured T cells from WT or RAGE2/2 mice in
conditions that directed differentiation into Th1, Th2, or Th17 T
cells. We confirmed the ability of the different culture conditions to
skew WT T cell differentiation, followed by a comparison of
cytokine production in WT and RAGE2/2 T cells cultured
under the cytokine-skewing conditions. When cultured in the
presence of anti-IFNc mAb and IL-4, we found similar production
of IL-4, IL-5, and IL-13 by T cells from RAGE2/2 and WT
mice, but increased production of IL-10 (Figure 4). However, there
was significantly lower levels of production of IFNc from T cells
cultured in the presence of IL-12 and anti-IL-4 mAb (p,0.001)
but greater production of IL-17 when the cells were cultured with
IL23, IL-6 and TGFb (p,0.001). The levels of IL-2 were similar
under all culture conditions in WT and RAGE2/2 cells
(25.662.19 pg/ml and 25.962.05 pg/ml in WT and RAGE2/2
cells respectively under Th1 skewing conditions.) These studies
suggest that there is a selective role of RAGE on differentiation of
T cells.
Discussion
The receptor for advanced glycation end products has been
implicated in T cell activation and differentiation through direct
and indirect evidence. Removal of RAGE ligands with soluble
RAGE can attenuate adaptive immune responses and RAGE2/2
mice and their T cells show reduced functional responses.
However, it has not been clear whether all cells are similarly
affected by RAGE, the previous studies had suggested a
predominant effect on Th1 responses. We therefore tested the
role of RAGE in OVA induced lung inflammation, a model of
human asthma, and evaluated the effects of RAGE deficiency on
T cell activation. Our data show that RAGE is required for T cell
activation and cytokine production in this model following
intranasal OVA immunization and there were reduced responses
that included IFNc, IL-5, and IL-10 production. RAGE deficient
mice showed reduced T cell infiltration of the lung and decreased
granulocyte and antigen specific T cell accumulation in BAL fluid.
When we studied RAGE2/2 T cells under conditions that cause
Figure 2. OVA specific OT-II CD4+Tcells showed reduced cytokine production and lung infiltration in OVA immunized mice. RAGE
sufficient or deficient OT-II TCR-Tg mice were immunized with intranasal OVA as described in Materials and Methods. (A) Luminex analysis of IFN-c
(left panel) and IL-5 (right panel) levels in the supernatant of OVA stimulated OT-II cells derived from mediastinal LNs of WT or RAGE2/2 mice
immunized with OVA. The levels of cytokines in unstimulated cultures were less than the lower limit of detection. Results from a single experiment
representative of experiments with 3 and 4 WT and RAGE2/2 OT-II mice respectively are shown (*p,0.05). IF staining of CD4+ (red) and DAPI (blue)
cells (B) and percent of infiltrating CD4+Vb5+ cell (C) (OT-II: n = 5, OT-II.RAGE2/2; n = 5; *p,0.04) in the lungs of OVA immunized OT-II and OT-
II.RAGE2/2 mice. We did not find T cell infiltration in animals that had not been previously exposed to OVA.
doi:10.1371/journal.pone.0095678.g002
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skewing of T cells subsets we found reduced levels of IFNc but
increased levels of IL-17 from RAGE2/2 T cells.
We have previously shown that T cell activation was greatly
impaired in MLR reactions of T cells from RAGE deficient mice
or following TTP488 (a small molecule inhibitor of RAGE) [3].
This reduction was associated with impaired proliferation and
diminished IFN-c and TNF-a production. In contrast, Th2-type
cytokines, such as IL5 and IL4, were increased in the absence of
RAGE, suggesting that RAGE may enhance Th2 immunity in
mice [3]. In addition, when T1D was adoptively transferred into
NOD/scid recipients by diabetogenic splenocytes, there was
increased expression of IL-10 and TGF-b in the pancreases when
the recipients were treated with soluble RAGE.
However, in this setting, we found decreased expression of both
Th1 and Th2 cytokines by the pathogenic OVA-II T cells but our
studies of T cells differentiation indicate that there is not a specific
effect of RAGE on differentiation of Th2 cells. Instead, our studies
now performed under culture conditions that lead to T cell
skewing show an effect on Th1 cell differentiation. This is similar
to our previous studies showing a direct role for RAGE expression
on T cells that when cultured with RAGE2/2 or WT dendritic
cells Similarly differences in cytokine levels in supernatants from
mixed lymphocyte reactions or following activation with anti-CD3
and anti-CD28 mAb have now been shown to depend on the
RAGE status of the Tcells [2,3]. The effects of RAGE deficiency
on priming of Th17 cells had not previously been studied. The
differences between our findings on cytokine production in vivo
and in vitro under conditions of T cell skewing may reflect the
more complex role of RAGE in T cell activation that manifests as
reduced total cytokine production in the setting of antigen
exposure in vivo. Indeed, in previous studies, we found reduced
proliferative responses of RAGE2/2 T cells in mixed lymphocyte
reactions as well as reduced proliferative responses of RAGE2/2
T cells in vitro[2,3].
RAGE is also expressed on pulmonary tissues and recent studies
have suggested that RAGE and its ligands may play a role in
obstructive pulmonary disease [11]. A potential limitation, of our
studies, therefore, is that the reduced expression of RAGE on
tissue cells could have modified the T cellular responses, perhaps
even explaining the changes in cytokine secretion that we
observed. However, our adoptive transfer studies of WT or
RAGE2/2 OT-II T cells suggest that there is a direct effect of
RAGE on T cell responses that does not require the participation
of tissue RAGE. Furthermore, our functional studies of T cells
suggest that there were differences in the responses of WT and
RAGE2/2 T cells.
These new observations add to studies in other experimental
settings and with human cells showing a consistent effect of RAGE
on the differentiation of T cells. The basis for this effect is not
known since studies to address the role of RAGE on early
activation events on T cells have not been done. Collectively these
and previous studies indicate that the effects of RAGE on T cell
Figure 3. RAGE2/2 OT-II T cells show reduced infiltration in
lung when transferred into WT hosts. Adoptive transfer experi-
ments were performed as described in Materials and Methods with OT-
II T cells from WT (n = 7) or RAGE2/2 (n = 6) mice. The total number of
cells were counted in the lungs after gating on CD4+Vb5.1/5.2+ T cells
that were detected by flow cytometry. There were reduced numbers of
Vb5.1/5.2+ T cells in the recipients of RAGE2/2 OT-II T cells (p = 0.08).
doi:10.1371/journal.pone.0095678.g003
Figure 4. RAGE deficiency reduces Th1 while enhancing Th17 differentiation in T cells. Purified T cells from WT or RAGE2/2 mice were
cultured under conditions that favor differentiation into Th1, Th2, or Th17 cells as described in Materials and Methods. After 4 days of primary
stimulation and one day of resting, cells were restimulated overnight with plate bound anti-CD3. The levels of cytokines in the supernatants were
measured by Luminex or by ELISA. The skewing of the cell phenotypes was verified by measurement of secreted cytokines in the cultures of WT cells.
The levels of IL-17 produced when the T cells were cultured withIL23, IL6 and TGF-b were increased in the RAGE2/2 T cells vs WT whereas the levels
of IFNc were reduced when the cells were cultured with anti-IL-4 mAb and IL12 (p,0.0001). (n = 9 to 10 each, WT=black bar, RAGE2/2=gray bar).
doi:10.1371/journal.pone.0095678.g004
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differentiation involves events in T cell differentiation proximal to
STAT signaling. We compared Erk signaling in RAGE2/2 and
WT T cells and did not identify a difference in this signaling
molecule, but evidence from other experimental systems have
shown a role of RAGE-heparin sulfate and RAGE-HMGB1
complexes on cell signaling [12,13,14]. Signaling through RAGE
involves interactions between the FH1 domain of mammalian
Diaphanous-1 that interacts with the cytoplasmic tail of RAGE
and can involve several intermediaries including NF-kB, MAPKs,
PI3K/Akt, Rho GTPases, Jak/STAT, and Src family kinases [15].
Thus several activation pathways may be affected by RAGE
signaling. Further studies will be required to identify those
pathways specifically affected that may lead to activation and
differentiation of T cells.
This report further illustrates a more general role of RAGE in T
cell activation than had been appreciated from previous studies
that had suggested effects that were limited to Th1 cells. These
new findings, together with our previous studies that showed
RAGE expression on unstimulated T cells from patients with
diabetes, indicate that its role may be extensive. Additional studies
on a molecular basis will be needed to address these unresolved
questions regarding T cell activation.
Author Contributions
Conceived and designed the experiments: EMA PPH OH AMS RC KCH.
Performed the experiments: EMA PPH OH. Analyzed the data: EMA
PPH OH KCH. Contributed reagents/materials/analysis tools: RC AMS.
Wrote the paper: EMA PPH KCH.
References
1. Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, et al. (2004) Blockade of late
stages of autoimmune diabetes by inhibition of the receptor for advanced
glycation end products. J Immunol 173: 1399–1405.
2. Moser B, Desai DD, Downie MP, Chen Y, Yan SF, et al. (2007) Receptor for
advanced glycation end products expression on T cells contributes to antigen-
specific cellular expansion in vivo. J Immunol 179: 8051–8058.
3. Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, et al. (2008) RAGE
ligation affects T cell activation and controls T cell differentiation. J Immunol
181: 4272–4278.
4. Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, et al. (2012)
RAGE expression in human T cells: a link between environmental factors and
adaptive immune responses. PLoS One 7: e34698.
5. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, et al. (2003) Suppression of
experimental autoimmune encephalomyelitis by selective blockade of enceph-
alitogenic T-cell infiltration of the central nervous system. Nat Med 9: 287–293.
6. Miniati M, Monti S, Basta G, Cocci F, Fornai E, et al. Soluble receptor for
advanced glycation end products in COPD: relationship with emphysema and
chronic cor pulmonale: a case-control study. Respir Res 12: 37.
7. Watanabe T, Asai K, Fujimoto H, Tanaka H, Kanazawa H, et al. Increased
levels of HMGB-1 and endogenous secretory RAGE in induced sputum from
asthmatic patients. Respir Med 105: 519–525.
8. Constant SL, Brogdon JL, Piggott DA, Herrick CA, Visintin I, et al. (2002)
Resident lung antigen-presenting cells have the capacity to promote Th2 T cell
differentiation in situ. J Clin Invest 110: 1441–1448.
9. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, et al. (2004)
Receptor for advanced glycation end products (RAGE) regulates sepsis but not
the adaptive immune response. J Clin Invest 113: 1641–1650.
10. Wu X, Mi Y, Yang H, Hu A, Zhang Q, et al. (2013) The activation of HMGB1
as a progression factor on inflammation response in normal human bronchial
epithelial cells through RAGE/JNK/NF-kappaB pathway. Mol Cell Biochem
380: 249–257.
11. Sukkar MB, Ullah MA, Gan WJ, Wark PA, Chung KF, et al. (2012) RAGE: a
new frontier in chronic airways disease. Br J Pharmacol 167: 1161–1176.
12. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, et al. (2007) Toll-like receptor
9-dependent activation by DNA-containing immune complexes is mediated by
HMGB1 and RAGE. Nat Immunol 8: 487–496.
13. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental
mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842–
853.
14. Xu D, Young JH, Krahn JM, Song D, Corbett KD, et al. (2013) Stable RAGE-
Heparan Sulfate Complexes Are Essential for Signal Transduction. ACS Chem
Biol.
15. Huang W, Liu Y, Li L, Zhang R, Liu W, et al. (2012) HMGB1 increases
permeability of the endothelial cell monolayer via RAGE and Src family tyrosine
kinase pathways. Inflammation 35: 350–362.
RAGE in OVA-Induced Asthma
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e95678
